Soligenix Receives UK Regulatory Innovation Designation for Rare Disease Therapy SGX945

Soligenix (SNGX) received Promising Innovative Medicine designation from the UK's Medicines and Healthcare products Regulatory Agency for its investigational therapy SGX945 (dusquetide) for the treatment of Behet's disease. This designation builds on previous regulatory recognitions granted to dusquetide and highlights the significance of regulatory recognitions in advancing drug-development programs, particularly in rare diseases where clinical pathways are complex and resource-intensive.